Top 50 Life Science Startup Investors in October 2023

Portfolio highlights

• AIRNA — AIRNA is on a mission to transform the lives of patients with rare and common diseases by pioneering thediscovery and development of RNA editing therapeutics.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
• Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
• Slingshot Biosciences — Precise, reliable, and repeatable results. With synthetic cell controls, these goals are achievable in your flow cytometry experiments. Reduce costs, save time and commercialize faster. Beads for spectral compensation, immunophenotyping, viability, and assay controls.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• RoboK — A Cambridge University spin-out building cost-effective 3D sensing software technology
• Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
• PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Portfolio highlights

• Evozyne — We have a new way of thinking about proteins. We've uncovered Nature's hidden rules to build Natural Machines. With our partners, we are changing the world.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.

Portfolio highlights

• Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
• BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
• Elicit — Elicit is an artificial intelligence research assistant that uses language models to help users automate research workflows. This research assistant finds relevant papers without a perfect keyword match, summarizes takeaways from the papers, and extracts key information from the papers.

Portfolio highlights

• Navenio — Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England.
• AlveoGene — Welcome to AlveoGene Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy More information
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

Portfolio highlights

• Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
• Avalyn Pharma — This does NOT display on the home page
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.

Portfolio highlights

• Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
• Pencil Biosciences — Next Generation Genome Editing Tool
• Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.

Portfolio highlights

• Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
• Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
• Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Portfolio highlights

• deepset — We build Haystack NLP framework and deepset Cloud enterprise ML/NLP SaaS platform. We help you implement NLP.
• Context.ai — Context.ai is product analytics for LLM applications. Understand your users and improve their experiences in your LLM powered products.
• EpiBiologics — EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• NMD Pharma — NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
• Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

Portfolio highlights

• Spruce Biosciences — Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.
• Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Portfolio highlights

• Aryn — Answer questions on all of your data.
• ClearFeed — Conversational Support Platform on Slack
• Reserv — We are a premier claims platform, born from state-of-the-art data intelligence and talent management technology.

Portfolio highlights

• BioLoomics — BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays.
• Erthos — erthos is a producer of biodegradable packaging materials intended to replace traditional polystyrene and polypropylene inputs.
• ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport

Portfolio highlights

• Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.

Portfolio highlights

• Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
• Axithra — Saving lives and improving health economics through significant advancement of therapeutic drug monitoring (TDM).
• Kiro — Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.

Portfolio highlights

• Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
• Aer Therapeutics — Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
• Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

Portfolio highlights

• Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
• Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
• Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.

Portfolio highlights

• Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
• OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
• Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Portfolio highlights

• CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
• BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
• CH4 Global — CH4 Global is bending the curve with climate change solutions. We leverage red seaweed to help with methane reduction. Learn more our AgTech Solutions today!
• Mach Industries — Mach Industries provides technology solutions for defense systems that are built using techniques for producing and combusting hydrogen from sources found in the field.

Portfolio highlights

• Andes — Andes empowers microbes to enable positive action against climate change.
• Dimension Inx — Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois.
• SURGE Therapeutics — SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.

Portfolio highlights

• Archangel Lightworks — Archangel Lightworks is integrating space and air assets using laser communication.
• Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
• Quantum Motion — One Hundred Qubits is Interesting. One Million is World-changing

Portfolio highlights

• Invirsa — Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.
• MentorcliQ — Mentoring programs that drive employee engagement, development, and retention with MentorcliQ's award-winning mentoring software and approach. See why our customers love us!
• SureImpact — SureImpact is a user-friendly, social services case management software that helps you track and report outcomes, measure participant needs, and demonstrate impact to funders.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
• Orbital Therapeutics — Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible.

Portfolio highlights

• Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
• COMPASS Pathways — COMPASS is a mental health care company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.
• ADARx Pharmaceuticals — ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.

Portfolio highlights

• Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
• Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
• Terray Therapeutics — Guided by our powerful AI capabilities, Terray leverages vast high-quality data to optimize the path from discovery to transformative therapeutics.

Portfolio highlights

• Delphi — Delphi is digital cloning that scales time, monetizes knowledge, and interacts audience at scale.
• Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
• Pivotal Commware — Pivotal Commware was established in 2016 to commercialize a breakthrough in electromagnetic physics, Holographic Beam Forming™ (HBF). Years ago, Pivotal’s founders recognized that wireless demand for data would outgrow the complex coding, multiplexing and modulation schemes that network operators have deployed thus far. Beamforming was theanswer, but existing high cost, size, weight and power-consuming (C-SWaP) solutions were not. That’s why Pivotal assembled a team experienced in advanced commercial antenna and RF circuit design, advanced DARPA technology programs, and, uniquely, active/nonlinear metamaterials. Beyond technology, Pivotal also offers the depth and breadth of skills to develop integrated, end-to-end solutions.

Portfolio highlights

• Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
• Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
• 64x Bio — 64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery.The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specificfocus on those used for cell and gene therapies.

Portfolio highlights

• Siren Biotechnology — Siren Biotechnology blends two revolutionary therapeutic technologies into one for a novel approach to treating cancer.AAV gene therapy and cytokine immunotherapy are two revolutionary treatment approaches that Siren Biotechnology has combined into a single, redesigned modality. This approach overcomes significant obstacles and entirely transformshow tumor cells are eliminated and anti-tumor immunity is stimulated.
• Foresight Diagnostics — Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw.
• Range Biotechnologies — We're dedicated to making health monitoring a reality. We develop tools that capture the molecular state of individuals to prevent disease and improve health.

Portfolio highlights

• Ideogram — Ideogram: Helping people become more creative.
• Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
• Genesis Therapeutics — Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction.The company was founded in 2019and based in South San Francisco, California.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
• Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Portfolio highlights

• Embrace — Stay informed with Embrace's mobile monitoring solutions. Optimize app performance & user experience with our comprehensive platform. Learn more now.
• Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
• Functional Finance — Automated FinOps for Insurance. Unify and automate all of your financial operations, workflows and servicing without replacing your current infrastructure.

Portfolio highlights

• Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
• Tridek-One — Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response.
• PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.

Portfolio highlights

• Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
• Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
• AmbAgon Therapeutics — AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

Portfolio highlights

• Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
• Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
• Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Portfolio highlights

• Canaery — Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.
• Parallel Bio — Parallel Bio uses human immune organoids to accelerate the discovery and development of treatments.
• EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.

Portfolio highlights

• Arzeda — Arzeda develops enzyme design technology that presents a new way of thinking about biocatalysis. The company was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology.
• Parse Biosciences — Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Learn more about how you can use the most scalable single cell platform on the market without the need for custom instrumentation.
• Lumen Bioscience — We are transforming the way drugs are developed and what they cost.

Portfolio highlights

• Doceree — Doceree is a pharmaceutical advertising & healthcare marketing company which helps in getting a better healthcare services
• Avalyn Pharma — This does NOT display on the home page
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

Portfolio highlights

• ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
• Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
• Bicara Therapeutics — Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.

Portfolio highlights

• Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
• PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
• Pencil Biosciences — Next Generation Genome Editing Tool

Portfolio highlights

• Dattak — Dattak offers cyber insurance solutions based on cybersecurity technologies. Their cybersecurity tools allow us to assess a company's level of cybersecurity without complex questionnaires. They provide their policyholders with a variety of cybersecurity tools to help them prevent and defend against cyberattacks.
• Atlendis Labs — Atlendis enables users to lend digital assets to real-world businesses on-chain. Choose your rate and control your portfolio. Start earning real yield today!
• Tribun Health — Tribun Health provides a complete digital pathology platform for diagnosis, prognosis and biomarker analysis.

Portfolio highlights

• Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
• Resourcify — Mein Recycling is developed by Resourcify GmbH from Hamburg. The app is the easiest solution for businesses to easily manage all of their waste, collections, and recyclers in one app, and for waste management companies to seamlessly connect with their customers online. Their vision is zero-waste: enabled with the digital transformation of the wastesector as the foundation for the circular economy.
• traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!